|View printer-friendly version|
|INC Research Partners with goBalto™ to Further Enhance Clinical Study Startup Solution|
Will Use goBalto Tracker Platform to Optimize Site Activation and Increase Efficiencies in Study Startup
SAN FRANCISCO, Jan. 8, 2013 /PRNewswire/ -- goBalto, Inc., a developer of new-generation web clinical research solutions, today announced that INC Research, a therapeutically-focused clinical research organization (CRO), has selected goBalto Tracker 2.0 as its global site activation solution. Tracker is a secure, web-based platform that enables study teams to track and manage site activation activities in clinical trials.
"We chose goBalto Tracker as part of our study startup solution because it offers enhanced visibility into the traditionally cumbersome process of activating sites for clinical trials," said Alistair Macdonald, Chief Operating Officer at INC Research. "The system creates efficiencies through streamlined communication among sites, sponsors and CROs. This ultimately drives shorter timelines and cost savings for our customers."
Tracker, goBalto's lead product, is a software-as-a-service (SaaS) application that helps small and large clinical research organizations (CROs), pharmaceutical, and medical device companies track multiple studies and keep managers on the same page during the site activation phase of a study. Configurable workflows allow study managers to implement and benchmark processes globally. The application shows real-time status that study managers can use to find process bottlenecks and optimize resources.
Jae Chung, Founding CEO of goBalto, stated "The clinical trial industry recognizes how important it is to get study startup right and INC Research is at the forefront of utilizing technology to benefit their study sponsors in this critical phase. We're very proud that INC Research has selected Tracker as its study startup solution to provide transparency and insight into the site initiation process."
About INC Research
CONTACT: Edwin Kim, +1-415-671-4372, email@example.com